Compare GBCI & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GBCI | AXSM |
|---|---|---|
| Founded | 1955 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.9B |
| IPO Year | N/A | 2015 |
| Metric | GBCI | AXSM |
|---|---|---|
| Price | $42.59 | $142.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 20 |
| Target Price | $51.80 | ★ $176.00 |
| AVG Volume (30 Days) | ★ 715.8K | 552.1K |
| Earning Date | 01-22-2026 | 11-03-2025 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | ★ 26.70 | N/A |
| EPS | ★ 2.05 | N/A |
| Revenue | ★ $900,148,000.00 | $561,263,000.00 |
| Revenue This Year | $13.46 | $63.66 |
| Revenue Next Year | $27.84 | $54.46 |
| P/E Ratio | $20.94 | ★ N/A |
| Revenue Growth | 15.35 | ★ 65.83 |
| 52 Week Low | $36.76 | $75.56 |
| 52 Week High | $58.54 | $152.94 |
| Indicator | GBCI | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 51.25 | 51.82 |
| Support Level | $41.93 | $147.97 |
| Resistance Level | $43.38 | $152.76 |
| Average True Range (ATR) | 1.24 | 5.01 |
| MACD | 0.35 | -0.48 |
| Stochastic Oscillator | 78.09 | 37.60 |
Glacier Bancorp Inc is a regional bank holding company providing commercial banking services to scores of communities through its wholly-owned bank subsidiary, Glacier Bank. The bank operates a multitude of banking offices in Montana, Idaho, Colorado, Utah, Washington, and Wyoming. The bank's various products and services include deposit, loans, and mortgage origination services, among others. The bank predominantly serves individuals, small- to medium-sized businesses, community organizations, and public entities. Glacier emphasizes both internal growth and growth through selective acquisitions. A majority of the bank's loan portfolio is in commercial real estate, while a majority of its net revenue is net interest income.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.